1
Sept 28 (Reuters) – Merck & Co Inc: * SAYS MERCK ENTERS EXCLUSIVE GLOBAL LICENSE DEAL WITH SCIBRUNCH THERAPEUTICS FOR INVESTIGATIONAL ORAL KRAS G12D (ON) INHIBITOR SPR2015 Source text Further company
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
